title: Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis.
abstract: BACKGROUND
  Various studies have investigated the efficacies of mometasone furoate monohydrate (MFM) and fluticasone propionate (FP) nasal sprays for adults. However, research on their effectiveness for children is limited. This study compares the efficacies of MFM and FP nasal sprays in pediatric patients with perennial-allergic rhinitis.
  
  
  METHODS
  For this study, 94 perennial allergic rhinitis patients aged 6-12 years were randomly assigned to two treatment groups: an MFM group and an FP group. Treatment was provided for 4 weeks. The effects of the two agents were compared using the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire and total symptom scores (TSSs). Nasal-peak expiratory flow rates and eosinophil percentage in nasal smears were also compared between the two groups.
  
  
  RESULTS
  Patients in the MFM group exhibited significant improvement in their TSS (t = -2.65, p < 0.05). A detailed TSS analysis showed MFM to be more effective for relieving nasal symptoms, whereas FP was more effective for relieving non-nasal symptoms. Patient questionnaire scores suggested a significant reduction in symptoms for both the MFM (t = -7.23, p < 0.01) and FP (t = -5.43, p < 0.01) groups. The flow rate test results indicated significant improvements in the MFM group (t = 2.27, p < 0.05).
  
  
  CONCLUSIONS
  Following the 4-week therapy, MFM provided greater improvement compared to FP for symptoms of childhood perennial-allergic rhinitis. Based on their TSSs, the MFM group experienced more effective relief of nasal symptoms, whereas the FP group experienced more effective relief of non-nasal symptoms.
authors.affiliation: Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
authors.forename: Ka-Kit
authors.initials: KK
authors.lastname: Mak
authors.forename: Min-Sho
authors.initials: MS
authors.lastname: Ku
authors.forename: Ko-Hsiu
authors.initials: KH
authors.lastname: Lu
authors.forename: Hai-Lun
authors.initials: HL
authors.lastname: Sun
authors.forename: Ko-Huang
authors.initials: KH
authors.lastname: Lue
mesh_terms: D000485:Allergens; D000730:Androstadienes / Q000008:administration & dosage*; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004391:Dust / Q000276:immunology; D005260:Female; D000068298:Fluticasone; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008925:Mites / Q000276:immunology; D000068656:Mometasone Furoate; D059085:Nasal Sprays; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D011244:Pregnadienediols / Q000008:administration & dosage*; D011446:Prospective Studies; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D000730:Androstadienes; D018926:Anti-Allergic Agents; D004391:Dust; D059085:Nasal Sprays; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D000068298:Fluticasone
keywords: Pediatric Rhinoconjunctivitis Quality of Life Questionnaire; allergic rhinitis; eosinophil; fluticasone propionate; mometasone furoate monohydrate; nasal peak expiratory flow rate; total symptom score